187 related articles for article (PubMed ID: 38135443)
1. Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.
Houston CJ; Alkhatib A; Einarsson GG; Tunney MM; Taggart CC; Downey DG
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38135443
[TBL] [Abstract][Full Text] [Related]
2. Anti-protease levels in cystic fibrosis are associated with lung function, recovery from pulmonary exacerbations and may be gender-related.
Essilfie AT; Houston N; Maniam P; Hartel G; Okano S; Reid DW
Respirology; 2023 Jun; 28(6):533-542. PubMed ID: 36642534
[TBL] [Abstract][Full Text] [Related]
3. Identification of proteomic signatures associated with COPD frequent exacerbators.
Sun P; Ye R; Wang C; Bai S; Zhao L
Life Sci; 2019 Aug; 230():1-9. PubMed ID: 31121174
[TBL] [Abstract][Full Text] [Related]
4. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
5. Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis.
Alicandro G; Bisogno A; Battezzati A; Bianchi ML; Corti F; Colombo C
J Cyst Fibros; 2014 May; 13(3):328-34. PubMed ID: 24291530
[TBL] [Abstract][Full Text] [Related]
6. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD.
Gompertz S; Bayley DL; Hill SL; Stockley RA
Thorax; 2001 Jan; 56(1):36-41. PubMed ID: 11120902
[TBL] [Abstract][Full Text] [Related]
7. Antiviral immunity is impaired in COPD patients with frequent exacerbations.
Singanayagam A; Loo SL; Calderazzo M; Finney LJ; Trujillo Torralbo MB; Bakhsoliani E; Girkin J; Veerati P; Pathinayake PS; Nichol KS; Reid A; Footitt J; Wark PAB; Grainge CL; Johnston SL; Bartlett NW; Mallia P
Am J Physiol Lung Cell Mol Physiol; 2019 Dec; 317(6):L893-L903. PubMed ID: 31513433
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects.
Sloane AJ; Lindner RA; Prasad SS; Sebastian LT; Pedersen SK; Robinson M; Bye PT; Nielson DW; Harry JL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1416-26. PubMed ID: 16166615
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.
Waters VJ; Stanojevic S; Sonneveld N; Klingel M; Grasemann H; Yau YC; Tullis E; Wilcox P; Freitag A; Chilvers M; Ratjen FA
J Cyst Fibros; 2015 Nov; 14(6):755-62. PubMed ID: 25690407
[TBL] [Abstract][Full Text] [Related]
10. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Sagel SD; Thompson V; Chmiel JF; Montgomery GS; Nasr SZ; Perkett E; Saavedra MT; Slovis B; Anthony MM; Emmett P; Heltshe SL
Ann Am Thorac Soc; 2015 May; 12(5):708-17. PubMed ID: 25714657
[TBL] [Abstract][Full Text] [Related]
11. Airway IL-1β and Systemic Inflammation as Predictors of Future Exacerbation Risk in Asthma and COPD.
Fu JJ; McDonald VM; Baines KJ; Gibson PG
Chest; 2015 Sep; 148(3):618-629. PubMed ID: 25950204
[TBL] [Abstract][Full Text] [Related]
12. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.
Ratjen F; Waters V; Klingel M; McDonald N; Dell S; Leahy TR; Yau Y; Grasemann H
Eur Respir J; 2016 Mar; 47(3):829-36. PubMed ID: 26585432
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.
Patel AR; Kowlessar BS; Donaldson GC; Mackay AJ; Singh R; George SN; Garcha DS; Wedzicha JA; Hurst JR
Am J Respir Crit Care Med; 2013 Nov; 188(9):1091-9. PubMed ID: 24033321
[TBL] [Abstract][Full Text] [Related]
14. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.
Sagel SD; Wagner BD; Anthony MM; Emmett P; Zemanick ET
Am J Respir Crit Care Med; 2012 Nov; 186(9):857-65. PubMed ID: 22904182
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.
Zemanick ET; Wagner BD; Harris JK; Wagener JS; Accurso FJ; Sagel SD
Pediatr Pulmonol; 2010 Jun; 45(6):569-77. PubMed ID: 20503282
[TBL] [Abstract][Full Text] [Related]
16. Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study.
Reilev M; Lykkegaard J; Halling A; Vestbo J; Søndergaard J; Pottegård A
NPJ Prim Care Respir Med; 2017 Apr; 27(1):25. PubMed ID: 28416794
[TBL] [Abstract][Full Text] [Related]
17. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH
J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770
[TBL] [Abstract][Full Text] [Related]
18. Sputum proteomics in inflammatory and suppurative respiratory diseases.
Gray RD; MacGregor G; Noble D; Imrie M; Dewar M; Boyd AC; Innes JA; Porteous DJ; Greening AP
Am J Respir Crit Care Med; 2008 Sep; 178(5):444-52. PubMed ID: 18565957
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Inflammatory Responses of the Frequent Exacerbator in Pulmonary Rehabilitation: A Prospective Cohort Study.
Jenkins AR; Holden NS; Gibbons LP; Jones AW
COPD; 2020 Jun; 17(3):253-260. PubMed ID: 32362176
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial peptides, disease severity and exacerbations in bronchiectasis.
Sibila O; Perea L; Cantó E; Shoemark A; Cassidy D; Smith AH; Suarez-Cuartin G; Rodrigo-Troyano A; Keir HR; Oriano M; Ong S; Vidal S; Blasi F; Aliberti S; Chalmers JD
Thorax; 2019 Sep; 74(9):835-842. PubMed ID: 31278172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
